Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1 / Phase 2interventionalRules rewrite

Phase 1 / Phase 2: testing Tributyrin for Parkinson Disease

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its whether it is safe and how hard side effects are to live with as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Official registry: https://clinicaltrials.gov/study/NCT07863180 · Prabesh Kanel · enrollment listed as 15

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Tributyrin, or Placebo. The registry lists allocation as randomized. This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its whether it is safe and how hard side effects are to live with as a potential treatment.

They plan to enroll about 15 people at Ann Arbor. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study

Interventions: Tributyrin, Placebo

Primary outcome (registry wording): Tolerability of tributyrin

Who it is for (from inclusion criteria)

  • Ages 45 Years to any
  • Male or Female, age 45 years and over
  • Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including
  • Vertical supranuclear gaze palsy
  • Repeated unprovoked falls OR tendency to fall on the pull test within 3 years
  • Access to the internet and webcam for virtual visits
  • Presence of a caregiver

Public study contact (from the registry)

Nathan Alexander

734-998-8422

natealex@med.umich.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07863180 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07863180?

Phase 1 / Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07863180?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary